Mediastinal large B cell lymphoma with sclerosis (MLBCLwS). Therapeutic results in 180 consecutive PTS: MACOP/VACOP-B improves the long term outcome. G

Todeschini S. Secchi, M. Lazzarino, E. Morra, U. Vitolo, M. Bertini, A. Ambrosetti, E. Gallo, F. Pasini, L. Orsucci, L. Gargantini, E. Brusamolino, E. Orlandi, A. Gabbas, C. Tarella, G. Rossi, M. Liberati, F. Menestrina, M. Paulli, C. Palestro, M. CantiniG. Pizzolo, G. Perona

Research output: Contribution to journalArticlepeer-review

Abstract

Between 1982 and 1999, 180 consecutive pts with MLCBCLwS were treated in 14 Italian centers. Median FU:79 mo(l-199+). Pts: F102, M 79(ratiol,29), m.age 39 yrs(1470), stage 1/11:114, III/IV:66; bulky mediastinum: 144(80%); BM involvement 4(2%); 28 stage IV pts had disease in the thorax, 27 beyond, 36% had kidney/adrenal glands involved. Results: Therapy pts CR NR/PROGR REL Event Free MACOP/VACOP-B 95 81/94(86)* 13/94(13.8) 6/81(7.4) 73/95(77)** CHOP 43 22/43(51)* 21/43(49) 5/22(22.7) 17/43(40)** IIIGEN+ PBSC 25 20/25 (80) 5/25 (20) 3/20 (15) 16/25 (64) MegaCHOP 9 5/9 (55.5) 4/9 (44.4) 1/5 (20) 4/9 (44.4) BACOD/PROMACE 6 3/6 3/6 3/6 PVEBEC 2 2/2 2/2 *P

Original languageEnglish
JournalBlood
Volume96
Issue number11 PART I
Publication statusPublished - 2000

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Mediastinal large B cell lymphoma with sclerosis (MLBCLwS). Therapeutic results in 180 consecutive PTS: MACOP/VACOP-B improves the long term outcome. G'. Together they form a unique fingerprint.

Cite this